The current standard treatment for chronic hepatitis C consists of the combination of
pegylated interferon and ribavirin. Although interferon is known to have potent antiviral …

Chronic hepatitis C virus (HCV) infection affects more than 170 million persons worldwide
and is responsible for the development of liver cirrhosis in many cases. Standard treatment …

Lethal mutagenesis has emerged as a novel potential therapeutic approach to treat viral
infections. Several studies have demonstrated that increases in the high mutation rates …

Background & Aims Ribavirin monotherapy is the preferred treatment for chronic hepatitis E,
although occasional treatment failure occurs. We present a patient with chronic hepatitis E …

Their extremely error-prone replication makes RNA viruses targets for lethal mutagenesis. In
the case of hepatitis C virus (HCV), the standard treatment includes ribavirin, a base analog …

The nucleoside analogue ribavirin (R) is mutagenic for foot-and-mouth disease virus
(FMDV). Passage of FMDV in the presence of increasing concentrations of R resulted in the …

Quasispecies dynamics mediates adaptability of RNA viruses through a number of
mechanisms reviewed in the present article, with emphasis on the medical implications for …

Ribavirin, a broad spectrum antiviral agent, in conjunction with interferon forms the current
standard of treatment for hepatitis C virus (HCV) infection in humans. While ribavirin alone …

There are virtually no antiviral drugs available for the treatment of infections with RNA
viruses. This is particularly worrisome since most of the highly pathogenic and emerging …

The preeminent mode of action of the broad-spectrum antiviral nucleoside ribavirin in the
therapy of chronic hepatitis C is currently unresolved. Particularly under contest are possible …